Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Icke-invasiv mediannervstimulering för att dämpa takyarytmier i förmaket efter kateterablation för förmaksflimmer (NEUROPULSE)

6 november 2026 uppdaterad av: Vivek Reddy, Icahn School of Medicine at Mount Sinai

Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF.

The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following:

  1. early (0-2 months) post-ablation arrhythmias that occur in the immediate post-ablation time period
  2. AF/AT/AFL recurrences between months 2-6 post-ablation.This is a prospective, controlled, double-blind, randomized trial. The first 15 patients will not be randomized and will receive the active median/vagal stimulation only (open label).

The Study will be conducted in up to 1 clinical site in the United States. This study will have 1:1 randomization (active median/vagal stimulation vs sham). The study has been given NSR designation from FDA--NO IDE.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

Study will include continuous ECG assessment at 2 (0 for the first 15 patients, open label), 6 and 22 weeks from enrollment for 2 weeks (for 4 weeks at the first measurement for the first 15 patients, open label) and at least daily single lead ECG assessments throughout the follow up period. The ECG's generated can be viewed by physicians only to assess the frequency of RR2 treatments and will not be used to alter any other aspects of standard of care, including medical management, which will continue according to standard of care throughout the study. Patients and investigators will be blinded during the trial. Patients with paroxysmal or persistent AF undergoing AF ablation will be recruited post ablation procedure during hospitalization. During screening/baseline visit, eligible patients will be randomized to either an active treatment or a sham group (1:1 accordingly). The first 15 eligible patients will not be randomized and will receive the active median/vagal stimulation only (open label).

Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. Patients will be ordered to measure at home, 2 min ECG measurements with the RR2 system, two times a day throughout the study and when feeling symptoms suspected related to AF (AF/AT/PAC).

In addition, Patients will be instructed to perform Neuromodulation sessions with the RR2 home care device. Once a day for the first 2 weeks followed by three times per week for the remaining duration of the study. Additional treatments, up to once daily, will be added during this period in case the patient feels symptom, verified on single lead ECG and site staff.

Treatments will be conducted for a period of 6 months. During the study, the patients will continue to take Standard of care medication. Medications will be recorded throughout the study.

Patient Diary will be dispensed and or APP diary questioners will be used by the subject in order to document symptoms suspected as related to arrhythmia events.

Studietyp

Interventionell

Inskrivning (Faktisk)

51

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • New York
      • New York, New York, Förenta staterna, 10029
        • Icahn School of Medicine at Mount Sinai

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

  • Men and women ages ≥18 years
  • Patients planned to undergo or undergoing AF ablation for paroxysmal or persistent AF and able to be randomized within 48 hours of the ablation procedure.
  • Ability and willingness to sign an informed consent form.
  • Ability and willingness to use CardiaCare RR2 device, continuous ECG monitoring, and has an available SmartPhone.

Exclusion Criteria

  • Rheumatic heart disease
  • Extensive atrial disease (* some patients may be determined to be screen failures following the ablation procedure).
  • Moderate to severe mitral stenosis or history of mitral valve replacement
  • Pacemaker or CRTD or any implanted electrical stimulating device
  • Unilateral or bilateral vagotomy
  • Peripheral neuropathy affecting the tested upper extremity.
  • Severe heart failure (New York Heart Association Class III or IV) within 90 days.
  • Recent (within 90 days) stroke or transient ischemic attack.
  • Recent (within 90 days) myocardial infarction.
  • Pregnancy or breast feeding.
  • Life expectancy <1 year for any medical condition
  • Currently enrolled in another study that would interfere with this study
  • Unsuitable for participating in the study according to attending physician

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Participants with CardiaCare RR2

Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users.

CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.

Sham Comparator: Participants with Sham Device

Sham device will be dispensed, which will create a sensation but not provide therapy

Sham device will be dispensed, which will create a sensation but not provide therapy

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
AF/AFL occurrence
Tidsram: at 2-months and 6-months post-ablation procedure

Burden of AF/AFL (defines as 30 seconds or longer) during the 2-months and 6-months period after ablation measured using ECG-patch monitoring and daily RR2 single lead ECG.

at 2-months and 6-months post-ablation procedure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Antal akutbesök
Tidsram: 6 månader efter ablation
6 månader efter ablation
Antal sjukhusvistelser
Tidsram: 6 månader efter ablation
6 månader efter ablation
Antal elkonverteringar
Tidsram: 6 månader efter ablation
6 månader efter ablation
Antal ablations-re-Dos
Tidsram: 6 månader efter ablation
6 månader efter ablation
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Tidsram: 2-month and 6-month post-ablation procedure

Time to first AT or AF recurrence measured by CardiaCare RR2

2-month and 6-month post-ablation procedure
Number of arrythmia occurrences
Tidsram: 2-month and 6-month post-ablation procedure

Burden of all arrythmias between 2- and 6-months period after ablation will be measured using 2 weeks ECG-patch monitoring and daily RR2 single lead ECG.

2-month and 6-month post-ablation procedure
Number of Atrial Arrythmia Symptoms
Tidsram: 6-month post-ablation procedure

Difference in Atrial Arrythmia Symptoms during the 6 months period after ablation.

6-month post-ablation procedure
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Tidsram: 6 months post-ablation

Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence during the 6-months period after ablation.

6 months post-ablation
Quality of Life measured using The European Heart Rhythm Association (EHRA) score
Tidsram: Baseline, 2-months, and 6-months

The investigators will assess the change in EHRA symptom scale. The EHRA score ranges from 1 to 4. Higher scores indicate more severe symptoms.

Baseline, 2-months, and 6-months
Quality of Life measured using Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Score
Tidsram: Baseline, 2-months, and 6-months

The AFEQT is a questionnaire assessing quality of life and symptoms in atrial fibrillation patients. It covers four subscales: patient symptoms, daily activities, treatment concerns, and treatment satisfaction. Subscales from 0-100, with Full Scale range from 0 to 100, with higher scores indicating better quality of life and fewer symptom burdens.

Baseline, 2-months, and 6-months
Change in PAC/AT/AFL before and after treatment with RR2
Tidsram: Baseline and 6-month post-ablation

Change, such as increase or decrease, in incidence/frequency of atrial arrhythmias before and after treatment with study device.

Baseline and 6-month post-ablation
Change in Heart Rate Variability (HRV)
Tidsram: Baseline and 6-month post-ablation

Heart rate variability (HRV) is the variation in the time interval between consecutive heartbeats. Higher HRV indicates better cardiovascular function and stress resilience.

Baseline and 6-month post-ablation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai
  • Huvudutredare: Mohit Turagam, MD, Icahn School of Medicine at MS

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 oktober 2024

Primärt slutförande (Faktisk)

30 juli 2026

Avslutad studie (Faktisk)

30 juli 2026

Studieregistreringsdatum

Först inskickad

19 december 2024

Först inskickad som uppfyllde QC-kriterierna

19 december 2024

Första postat (Faktisk)

27 december 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera